No profile data available.
Kymera Therapeutics, Inc. (KYMR) is a healthcare company in the skin treatment pharmaceuticals industry, based in Watertown, United States, with about 273 full-time employees.
It reported revenue of $39.21 million for fiscal year 2025, down 16.7% from fiscal year 2024, and net income of -$311.35 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $65.00 million, up 466.4% from a year before. Its market capitalization was $9.35 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Kymera Therapeutics reported $39.21 million in revenue for fiscal year 2025, down 16.7% from $47.07 million in fiscal year 2024. In Q2 2026 revenue was $65.00 million.
$9.35 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Krystal Biotech, Inc. (KRYS), Oruka Therapeutics, Inc. (ORKA), Arcutis Biotherapeutics, Inc. (ARQT), Almirall, S.a. (ALMRY).